Emerging therapeutic approaches for Tourette syndrome and other tic disorders - a systematic review of current clinical trials.

Autor: Häge A; Department of Child & Adolescent Psychiatry and Psychotherapy, Medical Faculty Mannheim, Central Institute of Mental Health, University of Heidelberg, J5, Mannheim, 68159, Germany. alexander.haege@zi-mannheim.de., Krämer R; Department of Child & Adolescent Psychiatry and Psychotherapy, Medical Faculty Mannheim, Central Institute of Mental Health, University of Heidelberg, J5, Mannheim, 68159, Germany., Dunlap M; Tics and Tourette Across the Globe (TTAG), A Global Non-Profit Advocacy Organization, Hannover Medical School, 30625, Hannover, Germany., Mechler K; Department of Child & Adolescent Psychiatry and Psychotherapy, Medical Faculty Mannheim, Central Institute of Mental Health, University of Heidelberg, J5, Mannheim, 68159, Germany., Müller-Vahl KR; Department of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School, Hannover, 30625, Germany., Nagy P; Department of Neurodevelopmental Disorders, Bethesda Children's Hospital, Budapest, Hungary.
Jazyk: angličtina
Zdroj: European child & adolescent psychiatry [Eur Child Adolesc Psychiatry] 2024 Dec 23. Date of Electronic Publication: 2024 Dec 23.
DOI: 10.1007/s00787-024-02637-x
Abstrakt: Tourette syndrome and other tic disorders are prevalent neurodevelopmental disorders typically treated with behavioral techniques or pharmacological interventions, primarily antipsychotics. However, many patients do not achieve sufficient response to conventional treatments, underscoring the need for further research in this area. To provide a comprehensive overview of ongoing research activities, we systematically searched the clinical registries of the World Health Organization (WHO) and of the United States National Institutes of Health (NIH) for currently planned or ongoing registered clinical studies. Our search identified 21 registered studies, of which seven focus specifically on pharmacological interventions. Potential candidates include the dopamine D1 antagonist ecopipam, the phosphodiesterase inhibitor gemlapodect, and cannabis-based therapies. Additionally, several studies are exploring behavioral interventions including Comprehensive Behavioral Interventions for Tics (CBIT) and mindfulness training, neurostimulation including MRI-navigated transcranial stimulation, theta burst stimulation, and deep brain stimulation, traditional Chinese medicine, and other approaches such as microbiota transplantation. Despite the range of research activities underway, the overall landscape remains limited. In this report we will discuss the findings, current developments, and relevant aspects concerning future research including clinical, scientific, and patient perspectives.
Competing Interests: Declarations. Competing interests: Alexander Häge has received compensation for serving as consultant or speaker for Shire–Takeda and Medice, unrelated to this work. In addition to serving as an investigator in various pharmaceutical trials accross different indications, he is currently a principle investigator for a Tourette study on ecopipam sponsored by Emalex. Konstantin Mechler has received compensation for serving as consultant or speaker for Takeda and Medice, unrelated to this work. In addition to serving as an investigator in various pharmaceutical trials accross different indications, he is currently an investigator for a Tourette study on ecopipam sponsored by Emalex. Kirsten R Müller-Vahl has received financial or material research support from EU (FP7-HEALTH-2011 No. 278367, FP7-PEOPLE-2012-ITN No. 316978), DFG: GZ MU 1527/3-1 and GZ MU 1527/3-2, BMBF: 01KG1421, National Institute of Mental Health (NIMH), Tourette Gesellschaft Deutschland e.V., Else-Kröner-Fresenius-Stiftung, GW pharmaceuticals, Almirall, Abide Therapeutics, Emalex Biosciences, Inc., Noema Pharma, CannaXan, and Therapix Biosiences.She has received consultant's and other honoraria from Abide Therapeutics, adjupharm, Alexion, AlphaSights Ltd., AMP Alternative Medical Products GmbH, Asavita GmbH, Becanex, Boehringer Ingelheim International GmbH, Bionorica Ethics GmbH, CannaMedical Pharma GmbH, Canopy Grouth, Columbia Care, CTC Communications Corp., DHMS Direct Health Medical Services Ltd., Demecan, Enua pharma, DHMS Direct Health Medical Services Ltd., Ethypharm GmbH, Eurox Group, Global Praxis Group Limited, Hormosan Pharma GmbH, Lundbeck, Marry Jane, MCI Germany, Neuraxpharm, Noema Pharma, Sanity Group, Stadapharm GmbH, Synendos Therapeutics AG, Syqe, Tilray, and Zambon. She is an advisory/scientific board member for Alexion, Branchenverband Cannabiswirtschaft e.V. (BvCW), CannaMedical Pharma GmbH, Bionorica Ethics GmbH, CannaXan GmbH, Canopy Growth, Columbia Care, Ethypharm GmbH, Hormosan Pharma GmbH, IMC Germany, Leafly Deutschland GmbH, Neuraxpharm, Sanity Group, Stadapharm GmbH, Synendos Therapeutics AG, Syqe Medical Ltd., Therapix Biosciences Ltd., and Tilray. She has received speaker’s fees from Agaplesion Frankfurter Diakonie Kliniken gemeinnützige GmbH, Almirall, Aphria Deutschland GmbH, Arbeitsgemeinschaft Cannabis als Medizin (ACM), Astra Zeneca, Bedrocan, Bundesverband pharmazeutischer Cannabinoidunternehmen (BPC), Camurus, canymed GmbH, CEREBRO SPAIN BIDCO S.L, Cogitando GmbH, Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde (DGPPN), Diplomado Internacional de Endocannabinología (Programa Universitario de Investigación en Salud - PUIS, UNAM), Dresden International University (DIU), Emalex, EpiCampusNord, Eurox Deutschland GmbH, Ever pharma GmbH, Four20 Pharma, Georgia Medical Cannabis Project (GMCP), Grow Group PLC, Landesamt für Soziales, Jugend und Versorgung Mainz, Hessische Landesstelle für Suchtfragen e.V. (HLS), Landschaftsverband Westfalen-Lippe, LIO Pharmaceuticals GmbH, Medizinischer Dienst Westfalen Lippe, Meinhardt Congress GmbH, PR Berater, Salus gGmbH - Fachklinikum Bernburg, Spectrum Therapeutics GmbH, streamedup! GmbH, Swiss Alpinopharm, SynopticCon GmbH, targoEvent GmbH, Takeda GmbH, Tilray, VFnK – Verein zur Förderung neurologisch Kranker e.V., von Mende Marketing GmbH, Wayland Group, and WeCann. She has received royalties from Deutsches Ärzteblatt, Der Neurologe und Psychiater, Elsevier, Medizinisch Wissenschaftliche Verlagsgesellschaft Berlin, and Kohlhammer. She served as a guest editor for Frontiers in Neurology on the research topic “The neurobiology and genetics of Gilles de la Tourette syndrome: new avenues through large-scale collaborative projects”, is an associate editor for “Cannabis and Cannabinoid Research” and an Editorial Board Member of “Medical Cannabis and Cannabinoids” und “MDPI-Reports” and a Scientific board member for “Zeitschrift für Allgemeinmedizin”.Peter Nagy has received consultancy fees from Medice, and conference participation support from Medice, Egis Pharmaceuticals and Medis Hungary. He is currently a principle investigator for a Tourette study on ecopipam sponsored by Emalex.Robert Krämer and Michele Dunlap have no conflict of interest.
(© 2024. Springer-Verlag GmbH Germany, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: